Overall, our findings suggest that the higher risks of mortality in women with ER+/PR-, ER-/PR+, and ER-/PR- tumors, compared to women with ER+/PR+ tumors, are largely independent of the various demographic and clinical tumor characteristics assessed in this study. This evidence concerns the gene PGR and neoplasm.